Enveric Biosciences Inc. Common Stock (ENVB)

FairStock Score: 59/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am a Graham-and-Buffett-style investor, so I begin with the business, not the stock chart. Enveric is a five-employee biotechnology company with no reported revenue in the periods I can see. Its lead candidate, EB-003, is still preclinical, and the pipeline includes other early compounds. That means there is no proven product, no customer, and no demonstrated moat, only the hope of scientific success. The financial record is ugly. In fiscal 2025, net income was -$8.8 million and diluted EPS was -$36.24; in fiscal 2024, net income was -$9.6 million and diluted EPS was -$228.48; in fiscal 2023, net income was -$17.3 million. More recently, in fiscal Q2 2026, the quarter ended 2026-06-30, the company reported net income of -$3.0 million and diluted EPS of -$0.76. FairStock's trailing free cash flow is -$8.6 million, a -136.6% FCF yield against the $6.3 million market cap. Its Piotroski F-Score is 0/9 and Altman Z-Score is -13.28, both warning signs of financial fragility. At the 2026-10-13 close of $1.40, the P/B of 0.68 suggests the market values it below book, which is the only classic value hook I see. But a low price relative to book is meaningless if book value is being burned to fund uncertain preclinical research. ROE of -170.04% and ROCE of -87.34% show capital is being destroyed, not compounded. Lynch category is none because of losses in each of the last four years. I would call this a speculative venture, not a value investment.

In plain English: Enveric is a tiny biotech trying to develop experimental medicines for mental health and brain conditions, but its main drug is still in early lab testing. It has no reported revenue in the recent filings and keeps losing money, including a net loss of $8.8 million in fiscal 2025 and $3.0 million in the quarter ended June 30, 2026. At $1.40, the stock may look cheap compared with its accounting value, but the business is very risky and unproven, so it is not a strong or stable company.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer